Shaping the future of animal health
Virbac group

2018 third quarter consolidated sales

Thursday, October 11, 2018 

Public release

 

Revenue grew by +5.5% at constant exchange rates at the end of September 2018

 

PR18-Q3-01.gif

Quarterly consolidated revenue
Group revenue reached €204.3 million in the third quarter, an increase of +6.1% at real rates when compared to the same period in 2017. At comparable exchange rates, third-quarter revenue saw faster growth than in the first half, showing sustained growth of +9.3%. The quarter’s growth is mainly driven by activity in the United States, which is enjoying a favorable base effect compared to the same period in 2017. It should be noted that ex-distributor sales in the United States of Virbac products to veterinary clinics are growing overall by +14%, with Sentinel and Iverhart posting growth of +7% and +45% respectively, compared to 2017. Latin America exclusive of Chile, driven by double-digit growth in Brazil and Mexico, and with Asia Pacific buoyed by China, New Zealand and Australia, contribute positively to growth, offsetting a stable Europe and declining Chile. In terms of species, growth originates primarily from the companion animal segment, with products such as parasiticides, petfood, vaccines and dermatology ranges. Furthermore, products for cattle, such as vaccines and food supplements, play a role in the quarter’s performance.

Cumulative revenue at the end of September
Revenue reached €634.3 million versus €630.2 million over the same period in 2017, recording total growth of +0.7%. Excluding the negative effect of exchange rates, notably the Indian rupee, the American and Australian dollar, and the Brazilian real, revenue is growing at +5.5%.

In the United States, activity grew by +6.4% at real rates, including +13.8% at comparable exchange rates, steadily improving since the beginning of the year. This performance is due to large sales of Sentinel in the third quarter, as well as by sustained performance in dental ranges and specialty products. It should be noted that ex-distributor sales in the United States of Virbac products to veterinary clinics are growing well at +6% at the end of September. Although Sentinel is now at just –1%, Iverhart ranges continue growing at +30%, and all other ranges post average growth of +19% at the end of September 2018.

Outside of the United States, the Group is stable at real rates at the end of September, however, organic growth remains strong at +4.5%. Europe shows growth of +2.5% at real rates, including+3.0% at constant rates, due to a good contribution by France, the United Kingdom, and Germany in particular, offsetting difficulties encountered in Southern Europe (competition facing the vaccine against canine leishmaniosis and declining antibiotic sales in Spain). In the rest of the world, the Asia-Pacific area shows a change of -1.9%, including +6% at constant exchange rates (+7.8% excluding an unfavorable base effect related to licensing revenue recognized in 2017), mainly due to momentum in India, New Zealand and Australia. Growth in Latin America, exclusive of Chile, amounted to +1.6% at real rates and +13.5% at constant rates, driven by activity in Brazil and Mexico. Lastly, Chile shows a decline of -11.5% at real rates, including -6.4% at constant rates, due in particular to weaker antibiotic and oral vaccine sales compared to the same period in 2017.

In terms of species, revenue in the companion animal segment is rising overall by +4.6%, including +8.4% at constant exchange rates. The ranges showing the most significant growth are the specialty ranges (especially Zoletil and Suprelorin), petfood, and the dental range, which offset the decline in parasiticide ranges. 

In the food producing animal segment, total change amounted to -3.6%, including +2.6% at constant exchange rates. Performance varies at constant rates, with the bovine sector growing at +8.1%, buoyed by nutritional products and ruminant vaccines, while industrial (swine and poultry) and aquaculture show respective declines of -3.8% and -14.8%, related to weaker sales of antibiotics and oral vaccines for salmon. 

Outlook
The Group anticipates growth in revenue at constant rates that should show a low single-digit increase in 2018 compared to 2017, and a current operating profit, before depreciation of assets arising from acquisitions ratio on revenue at constant exchange rates with growth at around 1 point at constant exchange rates compared to 2017. 

Debt relief should be around €30 million for the year at constant exchange rates. Furthermore, the Group obtained a relaxation of its financial agreement (net debt/Ebitda) with its bankers for 2018. Thus, it is at 5.0 at the end of June, 2018, and at 4.25 at the end of December, 2018. The Group’s financing is ensured primarily through an RCF (Revolving credit facility) line of 420 million euros, maturing in 2022, as well as bilateral bank loans, financing by the European Investment Bank (EIB) and Schuldschein disintermediated contracts, whose terms are between four and ten years.

PR18-Q3-02.gif

 

Back

Share on Facebook Share on Google Print current page Share on Twitter